- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Snapshot for Geron Corp (GERN)
| Open: | 1.4200 | Day's Range: | 1.3900 - 1.4200 | Volume: | 487,408 | Bid: | 1.3900 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 1.4200 | 52wk Range: | 1.3500 - 4.5000 | 1-Yr Rtn: | -68.54% | Ask: | 1.4000 |
Key Statistics for GERN
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E (12/2012) | - |
| Earnings Per Share (USD) (ttm) | -0.6700 |
| Est. EPS (USD) (12/2012) | -0.5930 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 184.92 |
| Shares Outstanding (M) | 132.09 |
| Enterprise Value (M USD) (ttm) | 48.78 |
| Enterprise Value/EBITDA (ttm) | - |
| Price/Book (mrq) | 1.4125 |
| Price/Sale (ttm) | 80.4870 |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 07/27/2012 |
More GERN Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for GERN
- Operating
- Investing
- Financing (M/USD)
Company Profile & Key Executives for GERN
Geron Corporation, a biopharmaceutical company, discovers and develops therapeutic and diagnostic products to treat cancer and other age-related degenerative diseases including spinal cord injury, heart failure and diabetes.
| Hoyoung HuhChairman | John A ScarlettPresident/CEO |
| Stephen M Kelsey "Steve"Exec VP/Chief Medical Officer | Stephen N RosenfieldExec VP/Secretary/Gen Counsel |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page